Enzymatica AB (publ)
STO:ENZY
Enzymatica AB (publ)
Cash from Operating Activities
Enzymatica AB (publ)
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Cash from Operating Activities
-kr60.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-4%
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Cash from Operating Activities
-kr244.9m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Orexo AB
STO:ORX
|
Cash from Operating Activities
-kr32.7m
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Camurus AB
STO:CAMX
|
Cash from Operating Activities
kr388m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Cash from Operating Activities
kr359.1m
|
CAGR 3-Years
42%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Cash from Operating Activities
-kr17m
|
CAGR 3-Years
48%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Enzymatica AB (publ)
Glance View
Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
See Also
What is Enzymatica AB (publ)'s Cash from Operating Activities?
Cash from Operating Activities
-60.5m
SEK
Based on the financial report for Dec 31, 2024, Enzymatica AB (publ)'s Cash from Operating Activities amounts to -60.5m SEK.
What is Enzymatica AB (publ)'s Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-4%
Over the last year, the Cash from Operating Activities growth was -50%. The average annual Cash from Operating Activities growth rates for Enzymatica AB (publ) have been -19% over the past three years , -10% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet